Dispatch Bio unveiled its Flare platform on 23 July, a first-in-class approach to treating solid tumours using virus-delivered universal antigens that mark cancer cells while disrupting immunosuppressive microenvironments. The technology combines tumour-targeted viral vectors with next-generation CAR-T therapies to trigger a cascade effect, where destroyed tumour cells release additional viral particles to label neighbouring malignancies.

Co-founded in 2022 by CAR-T pioneer Carl June, the company has raised USD 216 million from investors including ARCH Venture Partners and Bristol Myers Squibb to advance its lead candidate into Phase I trials by 2026.

According to PharmCube's MedAlpha® database, six investors participated in Dispatch's Series A. Click here to request a free trial for MedAlpha®.